Animalgesic Labs has recalled two batches of Animalgesics for Mice (buprenorphine HCl), an injectable pain medication for laboratory animals. Approximately 230 units were affected because they failed to meet internal quality and manufacturing specifications. The recall affects academic research facilities, private industry, and the National Institutes of Health that purchased the 3.0 mL vials directly or through Henry Schein Animal Health.
The drug product may not perform as expected because it did not meet required specifications, potentially resulting in ineffective pain management for the animals being treated. No specific incidents or injuries have been reported to date.
Veterinary drug refund and guidance.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response